Pharmacoeconomic analysis of type 2 diabetes mellitus by vildagliptin medication in Kazakhstan

This study is aimed to determine cost-effectiveness of vildagliptin in comparison with sitagliptin for the treatment of patients with type 2 diabetes mellitus (T2DM) from the perspective of Ministry of Health of the Republic of Kazakhstan

Pharmacoeconomic analysis of type 2 diabetes mellitus by vildagliptin medication in Kazakhstan

This study is aimed to determine cost-effectiveness of vildagliptin in comparison with sitagliptin for the treatment of patients with type 2 diabetes mellitus (T2DM) from the perspective of Ministry of Health of the Republic of Kazakhstan

PHP127 Development of Hta In Kazakhstan

HTA was introduced in Kazakhstan in 2009 as a result of an agreement of Kazakhstani Government with World Bank. As a consequence of this project, an HTA unit was created as part of Republican Centre of Healthcare Development(RCHD). There is lack of evidence on HTA concept in Kazakhstan, therefore, this research aims to gather information on the current state of development, processes and resources used in HTA in the country

PMS17 Cost-Effectiveness of denosumab vs. Brand or generic zoledronic acid in patients with prostate cancer in kazakhstan

A phase III clinical trial demonstrated the advantage of denosumab over zoledronic acid(ZA) in delaying the first on-study and subsequent skeletal-related events(SREs) in patients with prostate cancer(PC). Recently, generic ZA became available. The purpose of this study was to examine the cost-effectiveness of denosumab vs. brand or generic ZA in the prevention of SREs in Kazakhstani patients with PC

PIH18 Cost-Effectiveness Of 13-Valent Pneumococcal Conjugate Vaccination In Kazakhstan

The aim of the study was to investigate the cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV-13) programme for children in Kazakhstan from the perspective of Ministry of Health

PMS37 Cost-Effectiveness Analysis of Tocilizumab Verse Infliximab for the Patients With Rheumatoid Arthritis in Kazakhstan

The purpose of present study was to evaluate the cost-effectiveness of tocilizumab (TCZ) vs. infliximab (IFX) for the treatment of patients with rheumatoid arthritis (RA) from the perspective of Ministry of Health (MoH) over a patient lifetime horizon in Kazakhstan

PGI28 Cost-Effectiveness of Simeprevir Vs. Telaprevir for The Triple Therapy of Hepatitis C In Kazakhstan

Hepatitis C Virus(HCV) is a growing health problem in the world. The aim of this study is to estimate a cost-effectiveness of a triple therapy(TT) with simeprevir compared to a TT with telaprevir for the previously treated with double therapy HCV patients in Kazakhstan